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INTRODUCTION 1
The epidermal growth factor receptor (EGFR) is overexpressed in colorectal cancer (1) , and 2 plays an important role in cellular proliferation and metastasis in metastatic colorectal cancer 3 (mCRC) (2) . The RAS family of small GTPases plays a central role in signaling downstream 4 from the EGFR (3) . Activating mutations in RAS can result in persistent signaling in the 5 absence of ligand binding to the EGFR, and resistance to therapy with the anti-EGFR 6 monoclonal antibodies panitumumab and cetuximab (3, 4) . KRAS and NRAS activation result in 7 different patterns of intracellular signaling, and mutations in KRAS and NRAS arise in different 8 cellular contexts and are not functionally redundant (5) . KRAS exon 2 mutations are an 9 established predictive biomarker of lack of response to anti-EGFR therapy in mCRC patients (6-10 10) . These initial studies evaluated the most commonly occurring mutations in codons 12 and 11 13 of KRAS; predictive value of KRAS mutations beyond exon 2 and mutations in other RAS 12 enzymes (such as NRAS) were not assessed (6) (7) (8) (9) . Based on large retrospective analyses (11) 13 and results from hypothesis-generating studies employing next-generation sequencing 14 techniques (12, 13) , analyses of studies evaluating anti-EGFR therapies as first-line therapy for 15 mCRC demonstrated that additional activating mutations in KRAS exons 3, and 4 and NRAS 16 exons 2, 3, and 4 predicted lack of response to panitumumab plus FOLFOX as first-line 17 treatment (14, 15) . However, there is limited data evaluating panitumumab in combination with 18 irinotecan-based therapy by RAS status. 19 The primary analysis from the phase 3, randomized, controlled 20050181 study demonstrated a 20 significant improvement in median progression-free survival (PFS) and a trend toward 21 improvement in overall survival (OS) with panitumumab plus fluorouracil, leucovorin, and 22 
Study Design and Eligibility 3
This prospective-retrospective analysis used data from an open-label, randomized, multicenter, 4 phase 3 study comparing the efficacy of panitumumab plus FOLFIRI with FOLFIRI alone in 5 patients with previously treated mCRC (ClinicalTrials.gov, NCT0039183). The primary analysis 6 has been described previously (8) . PFS and OS in the primary analysis population were the 7 study's coprimary endpoints. Objective response rate (ORR) was a key secondary endpoint. 8
Tumor Specimens 9
For patients identified as wild-type KRAS exon 2 by an investigational-use-only assay in the 10 primary study (Therascreen ® KRAS Mutation Kit, Qiagen, Germantown, MD; LightCycler ® , 11
Roche Diagnostics, Indianapolis, IN), DNA for RAS analysis was extracted from banked 12 formalin-fixed paraffin-embedded patient tumor specimens (DNA Extraction Mini Kit, Qiagen, 13
Germantown, MD). Specimens containing <50% tumor area were macrodissected. 14
Extended RAS Analysis 15
Analysis of KRAS exon 3 (codons 59/61) and exon 4 (codons 117/146); NRAS exon 2 (codons 16 12/13), exon 3 (codons 59/61), and exon 4 (codons 117/146); and BRAF exon 15 (codon 600) 17 was performed using gold-standard bidirectional Sanger sequencing and WAVE-based 18 SURVEYOR ® Scan Kits (Transgenomic, Omaha, NE) was performed as previously described 19 (14) . Mutations and analysis methods were prespecified based on previous findings (14, (16) (17) (18) (19) . 20
The central testing laboratory was blinded to treatment assignment and patient outcome. 21
Assessments 22
Radiographic imaging (computed tomography/magnetic resonance imaging) was performed 23 every 8 weeks throughout the study. Survival was monitored at 3-month intervals during long-24 term follow-up. Adverse events (AEs) occurring during the treatment phase and up to 30 days 1 following the final dose of study drug were recorded and graded according to the NCI-CTCAE 2 v3.0 with modifications for specified skin and nail toxicities (20) . An independent data 3 monitoring committee oversaw the safety analysis. 4
Statistical Analysis 5
The statistical analysis plan for this RAS analysis was developed after the KRAS exon 2 6 analysis was unblinded but before the RAS and BRAF mutational analysis was done. Clinical 7 outcomes were from the primary analysis. 8
The primary objective was to evaluate by RAS and BRAF status the treatment effect of 9 panitumumab plus FOLFIRI versus FOLFIRI alone on PFS and OS in the primary analysis 10 population. For the purposes of this analysis, patients were characterized as having RAS 11 mutations if analysis identified any predefined activating mutation in KRAS or NRAS. Similarly, 12 patients were characterized as having RAS or BRAF mutations if any predefined RAS or BRAF 13 mutation was detected. 14 Hypothesis testing was exploratory and similar to that employed in extended RAS analysis of 15 the PRIME study (14) . A sequential testing scheme evaluated the treatment effect of 16 Baseline clinical/demographic characteristics were similar between treatment arms and between 13 patients with wild-type and mutated RAS, and were similar to the baseline demographics in the 14 wild-type KRAS exon 2 population as previously reported (Table 1) (8) . 15
Efficacy Outcomes by Tumor RAS Mutation Status 16
For PFS, the HR for panitumumab plus FOLFIRI versus FOLFIRI alone was 0.73 17 (95%CI=0.59-0.90;P=0.004; Figure 1A ) in patients with wild-type KRAS exon 2 compared with 18 0.70 (95%CI=0.54-0.91;P=0.007; Figure 1B) (22) and Law methods (23), did 1 not provide evidence of an influence of post-progression anti-EGFR therapy on OS time. 2
Patients with RAS mutations did not derive clinical benefit from panitumumab plus FOLFIRI and 3 there was no evidence that outcomes were worse or of a negative interaction between the 4 administered agents. Among patients with wild-type KRAS exon 2 but with other RAS 5 mutations, the HR for PFS for panitumumab plus FOLFIRI versus FOLFIRI alone was 0.89 6 (95%CI=0.56-1.42;P=0.63; Figure 2A ). Among patients with any RAS mutation, the HR for 7 PFS for panitumumab plus FOLFIRI versus FOLFIRI alone was 0.86 8 (95%CI=0.71-1.05;P=0.14; Figure 2B ). Findings were similar for OS (Figures 2C,D) in patients 9 with any RAS mutation. Among patients with mutated KRAS exon 2, the HR for PFS for 10 panitumumab plus FOLFIRI versus FOLFIRI was 0.85 (95%CI=0.68-1.06); for OS the HR was 11 0.94 (95%CI=0.76-1.15; Figure 3A ). 12
Quantitative interaction tests for the negative predictive value of RAS mutations beyond those in 13 KRAS exon 2 on panitumumab treatment effect were not statistically significant (PFS, P=0.37; 14 OS, P=0.93). 15
Efficacy Outcomes by Tumor BRAF Mutation Status 16
BRAF mutation status was not predictive of benefit with panitumumab. Among patients with 17 wild-type RAS and wild-type BRAF (n=376), the HR for panitumumab plus FOLFIRI versus 18
FOLFIRI alone was 0.68 (95%CI=0.51-0.90; 6.9 versus 5.5 months;P=0.006); similarly, in 19 patients with wild-type RAS and mutated BRAF (n=45), the HR for panitumumab plus FOLFIRI 20 versus FOLFIRI alone was 0.69 (95%CI=0.32-1.49; 2.5 versus 1.8 months;P=0.34; Figure 3A) months;P=0.20). Irrespective of assigned treatment, the HR for PFS favored patients with wild-1 type BRAF versus those with mutated BRAF (HR=0.28; 95%CI=0.20-0.40; n=421). For OS, 2 the HR was 0.25 (95%CI=0.18-0.36). The presence of a BRAF mutation was associated with 3 poorer prognosis ( Figure 3B ). 4
Tumor Response 5
In KRAS exon 2 wild-type patients, the ORR was 35% in the panitumumab plus FOLFIRI group 6 versus 10% in the FOLFIRI alone group, whereas in patients with wild-type RAS, the ORR was 7 41% in the panitumumab plus FOLFIRI group and 10% in the FOLFIRI alone group (Figure 4 ; 8   Table S2 ). ORR was similar for panitumumab plus FOLFIRI and FOLFIRI alone among 9 patients with any RAS mutation (15% versus 13%; Table S1 ) and for patients with mutated 10 KRAS exon 2 (13% versus 14%, respectively). Median duration of response was 9.3 months for 11 panitumumab plus FOLFIRI versus 7.7 months for FOLFIRI alone (Figure 4) . within the first 8 weeks of treatment compared with those receiving FOLFIRI alone (37% versus 20 7%; P<0.0001). Early tumor response and depth of response outcomes were more favorable in 21 panitumumab-treated wild-type RAS patients than panitumumab-treated wild-type KRAS exon 2 22
patients (Table S3) 
Adverse Events 1
The types, incidence rates, and severity of AEs were similar in patients with wild-type RAS and 2 mutated RAS in the panitumumab plus FOLFIRI arm ( Table 2) . Additionally, the nature and 3 frequency of incidence of AEs was similar to that previously reported for the wild-type KRAS 4 exon 2 population. (8) The most frequently occurring AEs reported among all patients were 5 diarrhea, fatigue, and neutropenia. The incidence of hypomagnesemia and skin toxicities were 6 higher with panitumumab plus FOLFIRI compared with FOLFIRI alone ( Routine KRAS exon 2 mutation testing has allowed for identification of mCRC patients more 3 likely to derive benefit from panitumumab. However, a substantial proportion of patients with 4 wild-type KRAS exon 2 mCRC do not respond to panitumumab therapy, and there is potential 5 for further refinement of patient selection. Results from this prospective-retrospective analysis 6 provide support for use of this regimen in patients with RAS wild-type mCRC. We found 7 improvements in the treatment effect for panitumumab plus FOLFIRI versus FOLFIRI alone for 8 both PFS and OS in the wild-type RAS mCRC group compared with the wild-type KRAS exon 2 9 mCRC group. Conversely, patients with RAS mutations beyond KRAS exon 2 or with any RAS 10 mutation were unlikely to benefit from addition of panitumumab to FOLFIRI. Although there was 11 a trend toward longer OS among wild-type KRAS exon 2/mutated other RAS patients (11.3 12 versus 9.2 months), PFS was similar (3.7 months in both groups), and exclusion of wild-type 13 RAS patients did not alter ORR. Importantly, there was no evidence of worsening of OS or PFS 14 with panitumumab treatment in the mutated RAS group. High These results strongly support routine RAS analysis in mCRC. Testing for RAS mutations 17 beyond KRAS exon 2 better predicts response to treatment and improves patient selection, 18 thereby sparing patients who are unlikely to respond potential toxicities associated with anti-19 EGFR therapy. Rates of RAS mutation beyond KRAS exon 2 from 10-26% (14,15, Patients with BRAF mutations had shorter estimated median PFS and OS than BRAF wild-type 3 patients, consistent with previous findings (11, 14, 33) . This difference in prognosis was 4 independent of patients' RAS mutation status or panitumumab treatment. In this study, BRAF 5 mutations did not have clear predictive value and the results do not provide support for BRAF 6 mutation testing to guide anti-EGFR therapy. However, the prognostic information might guide 7 other clinical decisions. To improve outcomes for these patients, recent studies have evaluated 8 feasibility of treatment with anti-EGFR antibodies and other targeted agents (38, 39) . 9
The 41% ORR in the wild-type RAS panitumumab group represents one of the highest rates patients receiving panitumumab plus irinotecan versus irinotecan alone was reported in the 1 PICCOLO study, but these outcomes may have been influenced by the Q3W treatment 2 schedule employed (44). These data were also in contrast to the results seen in the PRIME 3 (14) and OPUS (29) studies, in which outcomes were worse with panitumumab or cetuximab in 4 combination with oxaliplatin-containing therapy (FOLFOX) in patients with RAS-mutant tumors, 5 compared with FOLFOX alone. 6
Key limitations of this study was that RAS analysis was exploratory (not defined in the original 7 study protocol) and that results from the KRAS exon 2 analysis were known before this analysis 8 was initiated. Consequently, the potential for bias exists. However, the biomarker hypothesis 9 was developed before the mutational analysis was available and was limited to RAS/BRAF. 10
Moreover, tumor specimens and clinical outcome data were derived from a large randomized 11 phase 3 study, and the high rate of RAS ascertainment limited the potential for ascertainment 12 bias. RAS was evaluated using robust, widely available assay procedures. The small number 13 of patients in some groups limits our ability to draw conclusions regarding outcomes. A variety 14 of confounding factors (eg, post-progression therapy) might have limited our ability to detect 15 improvement in OS. 16
Results from this study provide compelling evidence for panitumumab plus irinotecan-based 17 therapy as an important second-line therapy for RAS wild-type patients supported by phase 3 18 evidence. Exclusion of patients with RAS mutations improved the benefit-risk profile of 19 panitumumab plus FOLFIRI in this setting. The totality of evidence supporting RAS analysis 20 supports use of these analytical techniques in upfront testing. A recent meta-analysis of 9 21 panitumumab and cetuximab studies found improvements in outcomes with extended RAS 22 analysis (45) . Patient-level meta-analyses across randomized studies (including this study, 23 PRIME (14), PEAK (15) , the 408 study (12, 13) , and ongoing 0007 study [ClinicalTrials.gov, 24 Research. Research. 
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